According to the study of Meng [30] at Peking University People’s Hospital, patients with recurrent ROP with plus disease(+)could receive repeated intravitreal injections of VEGF inhibitors, our recurrent ROP patients with plus disease(+)included in the present study all received intravitreal injection of 0.3 mg/0.03 ml ranibizumab to avoid laser-induced ocular complications after repeated full communication with the family members of the patients. This evidence concerns the gene VEGFA and retinopathy of prematurity.